BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsForeign · last filed 2025-02-12
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2024 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2022 was $144.00M, a 5.26% decline from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2021 was $152.00M, a 3.40% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2022-12-31 | $144.00M 10-K · filed 2025-02-12 |
| 2021-12-31 | $152.00M 10-K · filed 2024-02-13 |
| 2020-12-31 | $147.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $163.00M 10-K · filed 2022-02-09 |
| 2018-12-31 | $152.00M 10-K · filed 2021-02-10 |
| 2017-12-31 | $131.00M 10-K · filed 2020-02-24 |
| 2016-12-31 | $131.00M 10-K · filed 2019-02-25 |
| 2015-12-31 | $55.00M 10-K · filed 2018-02-13 |
| 2014-12-31 | $28.00M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |